Regulation and Function of Cytokines that Predict Prostate Cancer Metastasis
Abstract
Even though prostate cancer is the second leading cause of cancer related mortality in men in the United States, there is an ongoing concern that as a medical community we are over diagnosing, and hence over treating, the disease. Yet, patients at high-risk for metastatic progression are unfortunately treated too late. We hypothesized that tissue chemokines can be strong biomarker candidates for distinguishing patients with high risk for biochemical recurrence or metastatic progression of prostate cancer. Interestingly, the chemokine, CCL4, up regulated in patients with biochemical recurrence. In the past funding cycle, of which we had 4 months of funding due to a lab move, we demonstrated that neutralizing CCL4 reduced the proliferation of mouse prostate andenocarcinoma cells, TRAMP-C1. Further, CCL4 neutralization reduced cell adhesion to collagen I. Orthotopic grafting of TRAMP-C1 cells with prostatic stromal fibroblasts that expressed CCL4 had significantly larger tumors than the TRAMP-C1 tumors associated with vector control expressing stromal fibroblastic cells. Together the data suggested that the upregulation of CCL4 in patient prostatic tissues associated with tumor recurrence is biologically consequential to tumor progression.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2011
- Accession Number
- ADA553488
Entities
People
- Neil Bhowmick